NCT04655170 - Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

January 30, 2023

Study Completion Date

March 30, 2023

Conditions

COPD Exacerbation

Interventions

DRUG

Revefenacin (YUPELRI) & Formoterol (Perforomist)

Revefenacin is a Long-acting anticholinergics (LAMAs) and Formoterol is Long-acting bronchodilators, beta-agonists (LABAs).

DRUG

Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)

Albuterol Inhalation Aerosol (short-acting beta-agonists) \& Ipratropium Aerosol (short-acting anticholinergic)

Trial Locations (1)

RECRUITING

University of Tennessee Medical Center, Knoxville